CARsgen Therapeutics: First patient dosed in China Phase I trial of CT1190B

CARsgen Therapeutics announced that CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of patients with relapsed/refractory large B-cell lymphoma who have failed at least second-line standard therapy, has completed the first patient infusion in its Phase I registrational clinical trial in China; the results of its IIT study have been presented as a poster at the 2026 European Hematology Association Annual Congress.